Stock Analysis

M3 Third Quarter 2025 Earnings: Beats Expectations

TSE:2413
Source: Shutterstock

M3 (TSE:2413) Third Quarter 2025 Results

Key Financial Results

  • Revenue: JP¥80.7b (up 27% from 3Q 2024).
  • Net income: JP¥15.3b (up 16% from 3Q 2024).
  • Profit margin: 19% (down from 21% in 3Q 2024). The decrease in margin was driven by higher expenses.
  • EPS: JP¥22.46 (up from JP¥19.45 in 3Q 2024).
earnings-and-revenue-growth
TSE:2413 Earnings and Revenue Growth February 11th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

M3 Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 5.4%. Earnings per share (EPS) also surpassed analyst estimates by 12%.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Healthcare Services industry in Japan.

Performance of the Japanese Healthcare Services industry.

The company's shares are up 2.9% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We've done some analysis and you can see our take on M3's balance sheet.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About TSE:2413

M3

Provides medical-related services primarily to physicians and other healthcare professionals through Internet.

Excellent balance sheet average dividend payer.

Community Narratives

AstraZeneca's Oncology and Obesity Innovations Will Drive Revenue Growth by 10%
Fair Value SEK 2.55k|37.11% undervalued
Unike
Unike
Community Contributor
Leading the Charge in SME SaaS Innovation
Fair Value SEK 100.02|23.535% undervalued
Investingwilly
Investingwilly
Community Contributor
Brookfield Corporation is a solid BUY for a long-term portfolio
Fair Value CA$82.23|1.7389999999999999% overvalued
Jonataninho
Jonataninho
Community Contributor